• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, July 6, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Van Andel Institute scientist awarded $2.9 million to tackle insulin resistance, a driver of Type 2 diabetes

Bioengineer by Bioengineer
October 3, 2023
in Health
Reading Time: 3 mins read
0
Dr. Nick Burton
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Van Andel Institute’s Nick Burton, Ph.D., has earned a five-year, nearly $2.9 million New Innovator Award from the National Institutes of Health Common Fund to find new ways to fix or prevent insulin resistance, a key driver of Type 2 diabetes.  

Dr. Nick Burton

Credit: Courtesy of Van Andel Institute

Van Andel Institute’s Nick Burton, Ph.D., has earned a five-year, nearly $2.9 million New Innovator Award from the National Institutes of Health Common Fund to find new ways to fix or prevent insulin resistance, a key driver of Type 2 diabetes.  

Although manageable with treatment, there currently is no way to repair the underlying mechanisms that cause the disease. Furthermore, it remains unclear why some people are more prone to Type 2 diabetes while others are resistant. To find a solution, Burton and his team are turning to nature — namely, pinpointing bacteria that influence insulin production and signaling.

“The New Innovator Award will allow us to establish a protocol for identifying new species of bacteria that regulate insulin signaling and the mechanisms they use to do so. Insights from this work will help us understand why some people who eat similar diets are more susceptible to diabetes than others,” Burton said. “In the future, we hope this approach will lead to new therapeutic strategies for Type 2 diabetes.”

One in 10 people in the U.S. — more than 35 million people — have Type 2 diabetes. Another 96 million, or 38%, of people aged 18 and older have higher-than-normal blood sugar levels that put them at risk of developing the disease.

At the root of Type 2 diabetes is insulin resistance, which occurs when cells no longer respond to the hormone tasked with managing blood sugar. The resulting sustained increase in blood sugar can impede healthy function and contribute to ulcers, tough-to-treat infections, kidney problems, and tissue and nerve damage, among other symptoms. 

The New Innovator Award will enable Burton and his team to deploy the first-ever, large-scale screen for bacteria that modify insulin signaling. Analysis of initial samples gathered from a small-scale, proof-of-concept pilot conducted over the past year is ongoing, but the preliminary results are promising, Burton says.

“Growing evidence suggests bacteria that reside in the human gut help the body govern insulin levels,” he said. “We believe other bacteria species also are capable of impacting insulin. We hope to find novel bacteria, which would open a new realm of research with game-changing implications for health.”

The New Innovator Award was established in 2007 as part of the NIH Common Fund’s Director’s Awards and supports “unusually innovative research from early career investigators,” according to NIH.

Burton joined Van Andel Institute in 2021 as an assistant professor in the Department of Epigenetics. Prior to arriving in Grand Rapids, he was an independent Next Generation Fellow at the Centre for Trophoblast Research at University of Cambridge in the U.K.

Research reported in this publication was supported by the NIH Common Fund and administered by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under award no. DP2DK139569 (Burton). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

###

ABOUT VAN ANDEL INSTITUTE
Van Andel Institute (VAI) is committed to improving the health and enhancing the lives of current and future generations through cutting-edge biomedical research and innovative educational offerings. Established in Grand Rapids, Michigan, in 1996 by the Van Andel family, VAI is now home to more than 500 scientists, educators and support staff, who work with a growing number of national and international collaborators to foster discovery. The Institute’s scientists study the origins of cancer, Parkinson’s and other diseases and translate their findings into breakthrough prevention and treatment strategies. Our educators develop inquiry-based approaches for K-12 education to help students and teachers prepare the next generation of problem-solvers, while our Graduate School offers a rigorous, research-intensive Ph.D. program in molecular and cellular biology. Learn more at vai.org.

 



Share12Tweet8Share2ShareShareShare2

Related Posts

Flame retardant BDE-209 targets molecularly linked to ulcerative colitis

July 6, 2026

Kidney transplant outcomes in older adults studied by German researchers

July 6, 2026

Salmonella protein SopB curbs early inflammation to slow disease progression

July 6, 2026

Multi-metal cooperation drives lung cancer chemoresistance, reversed by MiADMSA

July 6, 2026

POPULAR NEWS

  • Detection of EDCs in Breast Milk and Infant Urine Up to Six Months Highlights Early Exposure Risks

    77 shares
    Share 31 Tweet 19
  • New Drug Candidate Developed at McMaster Shows Potential for Treating Brain Cancer

    58 shares
    Share 23 Tweet 15
  • Saying Goodbye to PGY-6: Pediatric Fellowship Realities

    103 shares
    Share 41 Tweet 26
  • KTU Researchers Explore Ultrasound’s Role in Enhancing Blood Flow Beyond Diagnostics

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Flame retardant BDE-209 targets molecularly linked to ulcerative colitis

Ultra-high frequency particle impacts mimic rockbursts to shatter hard rock

Kidney transplant outcomes in older adults studied by German researchers

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 83 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.